JP2014500960A - 骨格筋量および神経性状態のマーカーとしてのbin1発現 - Google Patents
骨格筋量および神経性状態のマーカーとしてのbin1発現 Download PDFInfo
- Publication number
- JP2014500960A JP2014500960A JP2013538809A JP2013538809A JP2014500960A JP 2014500960 A JP2014500960 A JP 2014500960A JP 2013538809 A JP2013538809 A JP 2013538809A JP 2013538809 A JP2013538809 A JP 2013538809A JP 2014500960 A JP2014500960 A JP 2014500960A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- bin1
- subject
- antibody
- skeletal muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 87
- 210000002027 skeletal muscle Anatomy 0.000 title claims abstract description 84
- 101000970561 Homo sapiens Myc box-dependent-interacting protein 1 Proteins 0.000 title claims abstract description 45
- 102100021970 Myc box-dependent-interacting protein 1 Human genes 0.000 title claims abstract description 40
- 230000000926 neurological effect Effects 0.000 title claims abstract description 12
- 239000003550 marker Substances 0.000 title abstract description 3
- 238000000034 method Methods 0.000 claims abstract description 104
- 210000003205 muscle Anatomy 0.000 claims abstract description 82
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 47
- 201000010099 disease Diseases 0.000 claims abstract description 45
- 230000003247 decreasing effect Effects 0.000 claims abstract description 16
- 230000007423 decrease Effects 0.000 claims abstract description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 69
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 53
- 229920001184 polypeptide Polymers 0.000 claims description 44
- 108010029485 Protein Isoforms Proteins 0.000 claims description 42
- 102000001708 Protein Isoforms Human genes 0.000 claims description 42
- 239000012472 biological sample Substances 0.000 claims description 36
- 210000004369 blood Anatomy 0.000 claims description 24
- 239000008280 blood Substances 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 206010003694 Atrophy Diseases 0.000 claims description 8
- 208000012902 Nervous system disease Diseases 0.000 claims description 8
- 208000025966 Neurological disease Diseases 0.000 claims description 8
- 230000037444 atrophy Effects 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 208000001076 sarcopenia Diseases 0.000 claims description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 3
- 230000004968 inflammatory condition Effects 0.000 claims description 3
- 230000001272 neurogenic effect Effects 0.000 claims description 3
- 230000002596 correlated effect Effects 0.000 abstract description 3
- 241000282414 Homo sapiens Species 0.000 description 55
- 239000012634 fragment Substances 0.000 description 43
- 108090000623 proteins and genes Proteins 0.000 description 37
- 241000282465 Canis Species 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 31
- 241000282472 Canis lupus familiaris Species 0.000 description 27
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 27
- 239000000523 sample Substances 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 27
- 210000002381 plasma Anatomy 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 22
- 210000004408 hybridoma Anatomy 0.000 description 20
- 239000013615 primer Substances 0.000 description 20
- 241000283690 Bos taurus Species 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 230000027455 binding Effects 0.000 description 18
- 239000000427 antigen Substances 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 108060003951 Immunoglobulin Proteins 0.000 description 15
- 102000018358 immunoglobulin Human genes 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 13
- 238000003757 reverse transcription PCR Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 6
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 6
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 235000013861 fat-free Nutrition 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000012417 linear regression Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000283073 Equus caballus Species 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102100031780 Endonuclease Human genes 0.000 description 4
- 108700039887 Essential Genes Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 4
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000002987 primer (paints) Substances 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 206010028289 Muscle atrophy Diseases 0.000 description 3
- 208000029549 Muscle injury Diseases 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 238000010802 RNA extraction kit Methods 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- -1 amphiphysin-like Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229940124452 immunizing agent Drugs 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000020763 muscle atrophy Effects 0.000 description 3
- 201000000585 muscular atrophy Diseases 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HNXQXTQTPAJEJL-UHFFFAOYSA-N 2-aminopteridin-4-ol Chemical compound C1=CN=C2NC(N)=NC(=O)C2=N1 HNXQXTQTPAJEJL-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000714266 Bovine leukemia virus Species 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010015719 Exsanguination Diseases 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 206010062261 spinal cord neoplasm Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000000819 Adrenocortical Hyperfunction Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000003130 Alcoholic Neuropathy Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000043859 Dynamin Human genes 0.000 description 1
- 108700021058 Dynamin Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000035211 Heart Murmurs Diseases 0.000 description 1
- 108010034145 Helminth Proteins Proteins 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 1
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000001055 Ischemic Contracture Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 206010051297 Soft tissue haemorrhage Diseases 0.000 description 1
- 206010048992 Spinal cord haemorrhage Diseases 0.000 description 1
- 208000007103 Spondylolisthesis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010042928 Syringomyelia Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 241000589499 Thermus thermophilus Species 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 244000238515 Thymus pulegioides Species 0.000 description 1
- 235000017715 Thymus pulegioides Nutrition 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 108010020713 Tth polymerase Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 208000009443 Vascular Malformations Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 201000000027 Volkmann contracture Diseases 0.000 description 1
- 102100032574 Voltage-dependent L-type calcium channel subunit alpha-1C Human genes 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000020701 alcoholic polyneuropathy Diseases 0.000 description 1
- 102000004111 amphiphysin Human genes 0.000 description 1
- 108090000686 amphiphysin Proteins 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000003712 glycosamine group Chemical group 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 108091008147 housekeeping proteins Proteins 0.000 description 1
- 102000052624 human CXCL8 Human genes 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000037120 immobility Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000028891 muscular glycogenosis Diseases 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 108010016910 synaptojanin Proteins 0.000 description 1
- 102000000580 synaptojanin Human genes 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 210000004341 tarsal joint Anatomy 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
【選択図】図1
Description
本出願は、2010年11月9日出願の米国特許仮出願第61/411,683号の利益を請求し、それは、参照により全体として本明細書に組み込まれる。
対象特徴。イヌを、BIN1レベルを判定するために選択した。使用されたイヌは、最小年齢が6ヶ月で、最大体重が2.3キログラム(kg)であった。イヌは、現在、活動性疾患の兆候がないか、または過去に病歴がなく、外見上健康であった。イヌは、以下の理由により除外された:a)過去96時間以内に運動をしたか、または上昇した体温を有した、b)イヌまたは人へのリスクのない、安全拘束を除外する難治性体内動態を有した、c)著しい皮膚疾患(例えば、皮膚炎、耳炎)、筋骨格障害(例えば、跛行、神経障害、筋萎縮)、腹部障害(例えば、触知腫瘤、器官形状の異常)、心疾患(例えば、頻脈、弱い/異常な末梢脈拍、著しい心雑音)、および呼吸器疾患(例えば、肺音の増加)等の疾患もしくは状態を有した、d)血漿BIN1テスト(最低0.5ml)および血漿化学パネルサブミッション(最低0.5ml)の両方のために十分な血液を得ることが不可能であった、e)著しい臓器機能不全の血漿プラズマ所見(例えば、クレアチンの上昇、肝臓酵素の増加等)を有した。
大規模なイヌ科研究を行い、血清BIN1および骨格特異的BIN1レベルと、臨床的に得られたパラメータ(例えば、年齢、体重、および筋量)との相互関係を判定した。0.5〜10歳の範囲の34匹の健康な純血種のハバニーズおよびシェルティーのイヌ科を研究した。上記に提供される基準を使用して、イヌ科を、研究のために選択し、表1および2は、研究に使用したイヌ科の内訳を示す。血清を、イヌ科から取得し、血清を使用し、捕捉酵素免疫測定法(ELISA)を使用して、BIN1タンパク質のレベルを測定した。
Claims (53)
- 対象における骨格筋量を判定する方法であって、
a.前記対象からの生体サンプル中のBIN1発現レベルを検出することと、
b.前記検出されたBIN1発現レベルを対照のBIN1発現レベルと比較することと、
を含み、前記対照レベルに対する前記BIN1発現レベルが、前記対象における骨格筋量を示す、方法。 - 前記対照レベルが正常であり、前記対照レベル未満の検出されたレベルが、前記対象における骨格筋量の低下を示し、前記対照レベルよりも高い検出されたレベルが、前記対象における筋量の増加を示す、請求項1に記載の方法。
- 前記対照レベルが正常より低く、前記対照レベルと同等か、またはそれ未満の検出されたレベルが、前記対象における骨格筋量の低下を示す、請求項1に記載の方法。
- 前記対照レベルが正常より高く、前記対照レベルと同等か、またはそれより高い検出されたレベルが、前記対象における骨格筋量の増加を示す、請求項1に記載の方法。
- 前記対象からの対照レベルよりも低い検出されたレベルが、前記対象における骨格筋量の減少を示す、請求項1に記載の方法。
- 前記対象からの対照レベルよりも高い検出されたレベルが、前記対象における骨格筋量の増加を示す、請求項1に記載の方法。
- 骨格筋量の低下に関連する疾患もしくは状態を有するか、または有する疑いがある対象を選択することをさらに含む、請求項1、2、および5に記載の方法。
- 前記疾患もしくは状態が、多発性硬化症、萎縮、神経原性萎縮、慢性炎症状態、およびサルコペニアからなる群から選択される、請求項7に記載の方法。
- 前記対象がサルコペニアを有するか、または有する疑いがある、請求項8に記載の方法。
- 前記BIN1が、骨格筋内に特異的に発現する、請求項1〜9に記載の方法。
- 前記BIN1が骨格筋特異的BIN1アイソフォームである、請求項10に記載の方法。
- 前記アイソフォームがBIN1アイソフォーム8である、請求項11に記載の方法。
- 前記骨格筋特異的BIN1アイソフォームが配列番号1を含む、請求項11に記載の方法。
- 前記骨格筋特異的BIN1アイソフォームが配列番号2を含む、請求項11に記載の方法。
- 前記BIN1発現レベルが、前記生体サンプル中のBIN1ポリペプチドを検出することによって、検出される、請求項1に記載の方法。
- 前記BIN1発現レベルが、前記生体サンプル中のBIN1をコードする核酸を検出することによって検出される、請求項1に記載の方法。
- 対象における骨格筋量の低下に関連する状態もしくは疾患を診断する方法であって、
a.前記対象からの生体サンプル中のBIN1発現レベルを検出することと、
b.前記検出されたBIN1発現レベルを対照のBIN1発現レベルと比較することと、
を含み、前記対照レベルに対する前記BIN1発現レベルが、前記対象が骨格筋量の低下に関連する疾患もしくは状態を有することを示す、方法。 - 前記対照レベルが正常であり、前記対照レベル未満の検出されたレベルが、前記対象が骨格筋量の低下に関連する疾患もしくは状態を有することを示す、請求項17に記載の方法。
- 前記対照レベルが正常より低く、前記対照レベルと同等か、またはそれ未満の検出されたレベルが、前記対象が骨格筋量の低下に関連する疾患もしくは状態を有することを示す、請求項17に記載の方法。
- 前記対象からの対照レベルよりも低い前記検出されたレベルが、前記対象が骨格筋量の低下に関連する疾患もしくは状態を有することを示す、請求項17に記載の方法。
- 骨格筋量の低下に関連する状態もしくは疾患を有するか、または有する疑いのある対象を選択することをさらに含む、請求項17〜20に記載の方法。
- 前記疾患もしくは状態が、多発性硬化症、萎縮、神経原性萎縮、慢性炎症状態、およびサルコペニアからなる群から選択される、請求項21に記載の方法。
- 前記対象がサルコペニアを有するか、または有する疑いがある、請求項22に記載の方法。
- 前記生体サンプルが血液または血漿である、請求項1〜23に記載の方法。
- 前記検出されたBIN1が、骨格筋内に特異的に発現する、請求項18〜24に記載の方法。
- 前記検出されたBIN1が、骨格筋特異的BIN1アイソフォームである、請求項25に記載の方法。
- 前記アイソフォームがBIN1アイソフォーム8である、請求項26に記載の方法。
- 前記筋特異的BIN1アイソフォームが配列番号1を含む、請求項26に記載の方法。
- 前記筋特異的BIN1アイソフォームが、配列番号2を含む、請求項26に記載の方法。
- 前記BIN1発現レベルが、前記生体サンプル中のBIN1ポリペプチドを検出することによって検出される、請求項17に記載の方法。
- 前記BIN1発現レベルが、前記生体サンプル中のBIN1をコードする核酸を検出することによって検出される、請求項17に記載の方法。
- 骨格筋内に特異的に発現するBIN1ポリペプチドに特異的に結合する単離された抗体。
- 前記BIN1ポリペプチドが、骨格筋特異的BIN1アイソフォームである、請求項32に記載の抗体。
- 前記BIN1アイソフォームがBIN1アイソフォーム8である、請求項33に記載の抗体。
- 前記筋特異的BIN1アイソフォームが配列番号1を含む、請求項33に記載の抗体。
- 前記筋特異的BIN1アイソフォームが配列番号2を含む、請求項33に記載の抗体。
- 前記抗体が配列番号2に特異的に結合する、請求項36に記載の抗体。
- 前記抗体が、モノクローナル抗体である、請求項32〜37のいずれか1項に記載の抗体。
- 配列番号8、配列番号9、および配列番号10を含むポリペプチド配列を有する軽鎖と、配列番号11、配列番号12、および配列番号13を含むポリペプチド配列を有する重鎖とを含む抗体と同一のエピトープ特異性を有する抗体。
- 前記抗体が、配列番号8、配列番号9、および配列番号10のポリペプチド配列を有する軽鎖と、配列番号11、配列番号12、および配列番号13を含むポリペプチド配列を有する重鎖とを含む、請求項39に記載の抗体。
- 前記軽鎖が配列番号5を含み、前記重鎖が配列番号7を含む、請求項40に記載の抗体。
- 配列番号18、配列番号19、および配列番号20を含むポリペプチド配列を有する軽鎖と、配列番号21、配列番号22、および配列番号23を含むポリペプチド配列を有する重鎖とを含む抗体と同一のエピトープ特異性を有する抗体。
- 前記抗体が、配列番号18、配列番号19、および配列番号20のポリペプチド配列を有する軽鎖と、配列番号21、配列番号22、および配列番号23を含むポリペプチド配列を有する重鎖とを含む、請求項42に記載の抗体。
- 前記軽鎖が配列番号15を含み、前記重鎖が配列番号17を含む、請求項43に記載の抗体。
- 配列番号28、配列番号29、および配列番号30を含むポリペプチド配列を有する軽鎖と、配列番号31、配列番号32、および配列番号33を含むポリペプチド配列を有する重鎖とを含む抗体と同一のエピトープ特異性を有する抗体。
- 前記抗体が、配列番号28、配列番号29、および配列番号30のポリペプチド配列を有する軽鎖と、配列番号31、配列番号32、および配列番号33を含むポリペプチド配列を有する重鎖とを含む、請求項45に記載の抗体。
- 前記軽鎖が配列番号25を含み、前記重鎖が配列番号27を含む、請求項46に記載の抗体。
- 対象における神経性状態もしくは疾患を診断する方法であって、
a.前記対象からの生体サンプル中のBIN1発現レベルを検出することと、
b.前記検出されたBIN1発現レベルを対照のBIN1発現レベルと比較することと、
を含み、前記対照レベルに対する前記BIN1発現レベルが、前記対象が、神経性疾患もしくは状態を有することを示す、方法。 - 前記生体サンプルが脳脊髄液(CSF)を含む、請求項48に記載の方法。
- 前記対照レベルが正常であり、前記対照レベル未満の検出されたレベルが、前記対象が神経性疾患もしくは状態を有することを示す、請求項48に記載の方法。
- 前記対照レベルが正常より低く、前記対照レベルと同等か、またはそれ未満の検出されたレベルが、前記対象が神経性疾患もしくは状態を有することを示す、請求項48に記載の方法。
- 前記対象からの対照レベルより低い検出されたレベルが、前記対象が神経性疾患もしくは状態を有することを示す、請求項48に記載の方法。
- 神経性状態もしくは疾患を有するか、または有する疑いのある対象を選択することをさらに含む、請求項48〜52に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41168310P | 2010-11-09 | 2010-11-09 | |
US61/411,683 | 2010-11-09 | ||
PCT/US2011/059574 WO2012087437A2 (en) | 2010-11-09 | 2011-11-07 | Bin1 expression as a marker of skeletal muscle mass and neurological conditions |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014500960A true JP2014500960A (ja) | 2014-01-16 |
JP2014500960A5 JP2014500960A5 (ja) | 2014-12-25 |
JP5866126B2 JP5866126B2 (ja) | 2016-02-17 |
Family
ID=46314702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013538809A Active JP5866126B2 (ja) | 2010-11-09 | 2011-11-07 | 骨格筋量および神経性状態のマーカーとしてのbin1発現 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9891232B2 (ja) |
EP (1) | EP2638403B1 (ja) |
JP (1) | JP5866126B2 (ja) |
AU (2) | AU2011345312A1 (ja) |
CA (1) | CA2817519C (ja) |
WO (1) | WO2012087437A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017009329A (ja) * | 2015-06-17 | 2017-01-12 | 花王株式会社 | 運動機能の判定用マーカー |
JP2017122655A (ja) * | 2016-01-07 | 2017-07-13 | 味の素株式会社 | 骨格筋面積の評価方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120094300A1 (en) | 2009-04-24 | 2012-04-19 | Robin Shaw | Bin1 as a Prognostic Marker in Cardiovascular Disease |
US8999659B2 (en) | 2010-10-20 | 2015-04-07 | The Regents Of The University Of California | Body fluid BIN1 as a marker of cardiac health |
EP2761298B1 (en) | 2011-09-30 | 2017-10-25 | Sarcotein Diagnostics, LLC | Bin1 expression as a marker of cancer |
CN107850589B (zh) | 2015-03-02 | 2020-07-24 | 萨克特恩诊断有限责任公司 | 13+/17+ bin1表达作为心脏病症的标记 |
CN112770723A (zh) * | 2018-07-25 | 2021-05-07 | 阿克罗斯生物科学公司 | 新型cldn 18.2特异性单克隆抗体及其使用方法 |
JP7442769B2 (ja) * | 2018-10-09 | 2024-03-05 | アイベックス バイオサイエンシーズ, インコーポレイテッド | フィラミンaに対する抗体およびその治療上の使用 |
US20240026034A1 (en) * | 2020-12-15 | 2024-01-25 | Arizona Board Of Regents On Behalf Of Arizona State University | Antibodies specific for qsox1 and methods of using the same |
CN112778414B (zh) * | 2020-12-31 | 2022-04-15 | 中南大学湘雅二医院 | cBIN1抗体及其应用 |
CN112794900B (zh) * | 2020-12-31 | 2022-10-25 | 中南大学湘雅二医院 | cBIN1抗体及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001004354A2 (en) * | 1999-07-07 | 2001-01-18 | Regeneron Pharmaceuticals, Inc. | Use of ras inhibitors of inhibiting muscle atrophy |
WO2010124240A2 (en) * | 2009-04-24 | 2010-10-28 | The Regents Of The University Of California | Bin1 as a prognostic marker in cardiovascular disease |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6048702A (en) * | 1995-05-05 | 2000-04-11 | The Wistar Institute Of Anatomy And Biology | Murine and human box-dependent myc-interacting protein (Bin1) and uses therefor |
US6831063B1 (en) * | 1999-08-31 | 2004-12-14 | The Wistar Institute Of Anatomy And Biology | Bridging Integrator-2(Bin2) nucleic acid molecules and proteins and uses therefor |
US20090088482A1 (en) * | 2003-10-14 | 2009-04-02 | The Trustees Of Columbia University In The City New York | Compositions and Methods For Treating Heart Failure |
ES2367311T3 (es) * | 2004-04-15 | 2011-11-02 | University Of Florida Research Foundation, Inc. | Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales. |
US20060003959A1 (en) * | 2004-06-10 | 2006-01-05 | Steven Burden | Methods and agents for maintaining muscle mass and for preventing muscle atrophy and biomarkers for monitoring same |
US20100086481A1 (en) | 2006-07-11 | 2010-04-08 | Baird Alison E | Differential expression of molecules associated with intra-cerebral hemorrhage |
US8999659B2 (en) * | 2010-10-20 | 2015-04-07 | The Regents Of The University Of California | Body fluid BIN1 as a marker of cardiac health |
-
2011
- 2011-11-07 WO PCT/US2011/059574 patent/WO2012087437A2/en active Application Filing
- 2011-11-07 JP JP2013538809A patent/JP5866126B2/ja active Active
- 2011-11-07 AU AU2011345312A patent/AU2011345312A1/en not_active Abandoned
- 2011-11-07 US US13/884,454 patent/US9891232B2/en active Active
- 2011-11-07 EP EP11850406.7A patent/EP2638403B1/en active Active
- 2011-11-07 CA CA2817519A patent/CA2817519C/en active Active
-
2017
- 2017-03-10 AU AU2017201661A patent/AU2017201661B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001004354A2 (en) * | 1999-07-07 | 2001-01-18 | Regeneron Pharmaceuticals, Inc. | Use of ras inhibitors of inhibiting muscle atrophy |
WO2010124240A2 (en) * | 2009-04-24 | 2010-10-28 | The Regents Of The University Of California | Bin1 as a prognostic marker in cardiovascular disease |
Non-Patent Citations (5)
Title |
---|
JPN6015030470; Acta Neuropathol (2011) 121:253-266 * |
JPN6015030472; Atlas Genet Cytogenet Oncol Haematol. 2009; 13(8) 543-548 * |
JPN6015030474; MOLECULAR AND CELLULAR BIOLOGY, Vol. 18, No. 1 Jan. 1998, p. 566-575 * |
JPN6015030480; THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 284, NO. 40, pp. 27674-27686, October 2, 2009 * |
JPN6015030483; Nat Genet. 2007 Sep;39(9):1134-9. Epub 2007 Aug 5 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017009329A (ja) * | 2015-06-17 | 2017-01-12 | 花王株式会社 | 運動機能の判定用マーカー |
JP2017122655A (ja) * | 2016-01-07 | 2017-07-13 | 味の素株式会社 | 骨格筋面積の評価方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2012087437A3 (en) | 2012-08-16 |
CA2817519A1 (en) | 2012-06-28 |
US9891232B2 (en) | 2018-02-13 |
CA2817519C (en) | 2020-01-14 |
EP2638403B1 (en) | 2017-03-22 |
AU2011345312A1 (en) | 2013-06-20 |
WO2012087437A2 (en) | 2012-06-28 |
EP2638403A4 (en) | 2014-05-07 |
AU2017201661B2 (en) | 2019-01-17 |
EP2638403A2 (en) | 2013-09-18 |
US20130324432A1 (en) | 2013-12-05 |
AU2017201661A1 (en) | 2017-03-30 |
JP5866126B2 (ja) | 2016-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5866126B2 (ja) | 骨格筋量および神経性状態のマーカーとしてのbin1発現 | |
JP2021509475A (ja) | 外傷性脳損傷を診断及び査定するための、新規のバイオマーカー及び方法 | |
KR20100135892A (ko) | 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법 | |
KR20200140400A (ko) | 집락 자극 인자 1 수용체(csf1r)에 결합하는 항체로 질환을 치료하는 방법 | |
US20090297527A1 (en) | Binding Domains of Proteins of the Repulsive Guidance Molecule (RGM) Protein Family and Functional Fragments Thereof, and Their Use | |
KR101092173B1 (ko) | A33 항원 및 jam-it의 용도 | |
EP3030249B1 (en) | Antibodies, compounds and derivatives thereof for use in the treatment of male infertility | |
US20080107600A1 (en) | Gene Marker And Composition For Diagnosis And Treatment Of Neurological Disorders And Diseases And Use Of The Same | |
KR20190006548A (ko) | 항-인자 ix 파두아 항체 | |
EP3244911B1 (en) | A method for determining a likely effect of a treatment to improve male infertility | |
EP3128326B1 (en) | Biomarker for diagnosis of aging or amyotrophia | |
JP2013039111A (ja) | スプライシングバリアント | |
JP2018522947A (ja) | 非アルコール性脂肪肝調節因子14−3−3タンパク質 | |
JP2018523656A (ja) | 非アルコール性脂肪肝調節因子14−3−3タンパク質 | |
EP2128272A1 (en) | Gene/protein marker for prediction or diagnosis of pharmacological efficacy of aurora a inhibitor | |
KR20170001344A (ko) | 비만 진단용 마커 tm4sf19 및 이를 이용한 방법 | |
US6680172B1 (en) | Treatments and markers for cancers of the central nervous system | |
EP3133400B1 (en) | Use of ak6 and gpx5 male fertility related proteins or combination thereof | |
CN101365718A (zh) | 血管老化预测因子及其使用 | |
AU2003256621A1 (en) | Methods for identifying compounds for regulating muscle mass or function using dopamine receptors | |
KR101849685B1 (ko) | 샤르코-마리-투스병 제1형의 원인 유전자로서 pmp22 및 이를 이용한 상기 질병의 진단방법 | |
US9638699B2 (en) | Biomarkers of oxidative stress | |
CN110499365A (zh) | Agap9在制备诊断骨关节炎的产品中的应用 | |
KR20200112069A (ko) | 골 질환의 예방 또는 치료를 위한 Jmjd2b 억제제의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141106 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141106 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150729 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150730 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151023 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151130 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151230 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5866126 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |